• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.

作者信息

Fiorelli Elisa Maria, Rossi Roberta Elisa

机构信息

Department of Internal Medicine, Fondazione IRCSS Ca' Granda, Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milano, Italy.

Department of Gastroenterology and Endoscopy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico and Department of Pathophysiology and Organ Transplant, Università degli Studi di Milano, Milan, Italy.

出版信息

Intern Emerg Med. 2018 Oct;13(7):1089-1091. doi: 10.1007/s11739-018-1886-y. Epub 2018 Jun 12.

DOI:10.1007/s11739-018-1886-y
PMID:29948831
Abstract
摘要

相似文献

1
Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.依度沙班用于治疗癌症相关静脉血栓栓塞，作为低分子肝素的替代药物。
Intern Emerg Med. 2018 Oct;13(7):1089-1091. doi: 10.1007/s11739-018-1886-y. Epub 2018 Jun 12.
2
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism.依度沙班在治疗癌症相关静脉血栓栓塞方面不劣于低分子量肝素。
BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29.
3
Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.比较新型 Xa 因子抑制剂依度沙班与未分级肝素、达肝素、来匹卢定和华法林在大鼠体内的抗栓和出血效果。
Thromb Res. 2013 Aug;132(2):234-9. doi: 10.1016/j.thromres.2013.05.020. Epub 2013 Jun 12.
4
[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].[北斋-VTE：依度沙班与华法林治疗症状性静脉血栓栓塞症的比较]
Rev Med Liege. 2013 Oct;68(10):548-51.
5
Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins.直接口服抗凝剂与癌症：低分子肝素尚未落幕。
Lancet Haematol. 2016 Aug;3(8):e357-8. doi: 10.1016/S2352-3026(16)30065-5. Epub 2016 Jul 1.
6
Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review.依度沙班治疗原发性纵隔精原细胞瘤头臂静脉血栓形成：病例报告及文献复习。
Medicine (Baltimore). 2022 Aug 26;101(34):e29429. doi: 10.1097/MD.0000000000029429.
7
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.新型口服抗凝剂治疗静脉血栓栓塞症的临床经验。
Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):513-9. doi: 10.1161/ATVBAHA.114.303396. Epub 2014 Aug 14.
8
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.依度沙班在肿瘤缩小后的非小细胞肺癌患者静脉血栓栓塞复发治疗中的成功应用
Intern Med. 2018 Jun 15;57(12):1769-1772. doi: 10.2169/internalmedicine.9741-17. Epub 2018 Feb 9.
9
[Prevalence, indication and compliance with the recommendations of prescription of low molecular weight heparin in oncology].[肿瘤学中低分子量肝素处方建议的患病率、适应证及依从性]
Bull Cancer. 2015 Nov;102(11):898-905. doi: 10.1016/j.bulcan.2015.09.003. Epub 2015 Oct 21.
10
Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.基于北里-静脉血栓栓塞症（Hokusai-VTE）研究的依度沙班治疗静脉血栓栓塞症的成本效益
Hosp Pract (1995). 2015;43(5):249-57. doi: 10.1080/21548331.2015.1099412. Epub 2015 Nov 7.

引用本文的文献

1
Successful Multimodal Treatment of Pancreatic Cancer With Extensive Superior Mesenteric Vein Thrombosis Utilizing Chemotherapy Combined With Direct Oral Anticoagulant.采用化疗联合直接口服抗凝剂成功多模式治疗伴有广泛肠系膜上静脉血栓形成的胰腺癌
Cureus. 2024 Feb 5;16(2):e53657. doi: 10.7759/cureus.53657. eCollection 2024 Feb.
2
A focus on direct oral anticoagulants: "old" and possible new indications and efforts for a better clinical management.聚焦直接口服抗凝剂：“旧”有及可能的新适应症以及改善临床管理的努力。
Intern Emerg Med. 2018 Oct;13(7):985-988. doi: 10.1007/s11739-018-1954-3. Epub 2018 Sep 21.

本文引用的文献

1
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.依度沙班治疗癌症相关静脉血栓栓塞症。
N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.
2
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.替扎肝素与华法林治疗活动性癌症患者急性静脉血栓栓塞症的随机临床试验。
JAMA. 2015 Aug 18;314(7):677-686. doi: 10.1001/jama.2015.9243.
3
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
新型口服抗凝剂治疗癌症患者静脉血栓栓塞的利弊
Intern Emerg Med. 2015 Sep;10(6):651-6. doi: 10.1007/s11739-015-1233-5. Epub 2015 Apr 4.
4
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.癌症患者静脉血栓栓塞症长期治疗的抗凝治疗
Cochrane Database Syst Rev. 2014 Jul 8(7):CD006650. doi: 10.1002/14651858.CD006650.pub4.
5
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.低分子量肝素与香豆素类药物用于预防癌症患者复发性静脉血栓栓塞的比较
N Engl J Med. 2003 Jul 10;349(2):146-53. doi: 10.1056/NEJMoa025313.